4D Molecular Therapeutics
FDMT
88 hedge funds and large institutions have $221M invested in 4D Molecular Therapeutics in 2022 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 28 increasing their positions, 28 reducing their positions, and 15 closing their positions.
22% more capital invested
Capital invested by funds: $182M → $221M (+$39.3M)
4.37% more ownership
Funds ownership: 80.53% → 84.9% (+4.4%)
0% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 28
7% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 15
1% less funds holding
Funds holding: 89 → 88 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$15.5M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$11.8M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.71M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.3M |
| 5 |
EHI
Eagle Health Investments
Greenwich,
Connecticut
|
+$969K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$7.77M |
| 2 |
CC
Casdin Capital
New York
|
-$3.88M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.73M |
| 4 |
Renaissance Technologies
New York
|
-$1.73M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
-$1.2M |
FDMT Hedge Fund Activity: Q3 2022 in Review
88 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q3 2022, worth a combined $221M — up 22% from $182M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of FDMT and 14 opened new positions — a net loss of 1 holder — while 28 trimmed existing stakes and 28 added.
The largest buyer was Morgan Stanley, adding an estimated $15.5M. The largest seller was Aquilo Capital Management, cutting an estimated $7.77M.
- 88 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q3 2022, down from 89 in Q2 2022.
- Funds reported $221M of 4D Molecular Therapeutics stock for Q3 2022, up 22% quarter-over-quarter.
- 14 funds opened new 4D Molecular Therapeutics positions in Q3 2022 and 15 closed out, a net change of -1 holder.
- The largest 4D Molecular Therapeutics buyer in Q3 2022 was Morgan Stanley, an estimated $15.5M added.
- The largest 4D Molecular Therapeutics seller in Q3 2022 was Aquilo Capital Management, an estimated $7.77M sold.
Based on aggregated 13F filings for Q3 2022.